What role do antiarrhythmic medications play in the long-term management and prevention of recurrent ventricular tachycardia?

Antiarrhythmic medications play a nuanced role in the long-term management and prevention of recurrent ventricular tachycardia (VT). Their use is generally considered when other interventions, such as catheter ablation or implantable cardioverter-defibrillators (ICDs), are either unsuitable or insufficient to control arrhythmia recurrence. In patients with recurrent VT, antiarrhythmic drugs can reduce the frequency of VT episodes and ICD shocks, thereby improving quality of life and potentially reducing morbidity. However, the choice of antiarrhythmic agent must be individualized, taking into account the patient's underlying cardiac pathology, comorbidities, and risk of proarrhythmia or adverse effects ¹.

Specifically, class III agents such as amiodarone are often used for long-term suppression of VT, especially in patients with structural heart disease or left ventricular impairment, due to their efficacy in reducing arrhythmia recurrence. Beta-blockers are also a cornerstone in managing ventricular arrhythmias, given their mortality benefit and role in reducing sympathetic triggers of VT ¹. Other class I agents are generally avoided in patients with structural heart disease due to proarrhythmic risks ¹.

Recent systematic reviews and meta-analyses of randomized controlled trials indicate that while antiarrhythmic drugs can be effective in reducing VT episodes, catheter ablation may offer superior long-term control in selected patients, particularly those with ICDs experiencing frequent shocks. Nonetheless, antiarrhythmic drugs remain a critical adjunct or alternative when ablation is contraindicated or incomplete (Kheiri et al., 2019). Acute management literature also supports the use of antiarrhythmics in stabilizing VT episodes but emphasizes the importance of individualized therapy and specialist input (Deneke et al., 2020; Dresen and Ferguson, 2018).

In summary, antiarrhythmic medications are integral to the long-term management of recurrent VT, primarily to suppress arrhythmia recurrence and reduce ICD interventions, with amiodarone and beta-blockers being the mainstays. Their use should be carefully balanced against potential risks, and they are often used in conjunction with or as an alternative to catheter ablation depending on patient-specific factors ¹ (Kheiri et al., 2019; Deneke et al., 2020).